Co-Hilos

Quick links to important sections

Co-Hilos

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Co-Hilos

Quick Facts

Property Description
Active ingredient Losartan and Hydrochlorothiazide (HCTZ)
Form Film-coated tablet
Pharmacological class Antihypertensive Combination (ARB + Diuretic)
Common use Reduction of high blood pressure
Origin Synthetic/Small Molecule

Co-Hilos: A Single-Pill Solution for High Blood Pressure

Co-Hilos is a prescription-only medicine that combines two active ingredients into a single, film-coated tablet for the treatment of high blood pressure (hypertension). This medicine belongs to the antihypertensive pharmacological class, and its use is typically reserved for adults whose blood pressure is not adequately controlled by either of the components taken alone. This fixed-dose combination strategy is clinically recognized for achieving greater blood pressure reduction than single-agent therapy in many patients.


Composition and Differentiation

Co-Hilos is the combination of Losartan, an Angiotensin II Receptor Blocker (ARB), and Hydrochlorothiazide (HCTZ), a Thiazide Diuretic. This blend is structurally differentiated by Losartan’s unique property among ARBs to also affect serum uric acid levels, which may help offset one of the potential effects of the diuretic component. The drug is classified as a synthetic, small-molecule product designed for once-daily oral administration. Though Co-Hilos may be a specific brand name, the chemical combination of losartan/hydrochlorothiazide is widely available globally under other brands, such as Hyzaar or various generic formulations.


Why Does it Combine Two Medications?

The two active ingredients are combined because they work through different and complementary mechanisms, leading to more powerful control than either ingredient alone. The combination is a common therapeutic strategy recommended by clinical guidelines because it simultaneously addresses both the tightening of blood vessels (Losartan) and the body's fluid volume (HCTZ). This synergistic effect provides comprehensive blood pressure management in a single tablet.

What side effects are possible with Co-Hilos?

Possible side effects and safety information

The safety profile of Co-Hilos (Losartan/Hydrochlorothiazide) is defined by officially documented adverse reactions classified by frequency and affected body systems, as established by governmental regulatory agencies. This framework helps distinguish between common, expected effects and rare, clinically significant events.

Adverse Reaction Classification

Adverse reactions are organized by the system they affect and their documented frequency in regulatory labeling:

Classification Examples of Reactions
Common Dizziness, headache, nausea, fatigue, cough.
Uncommon Palpitations, chest pain, insomnia, abdominal pain, rash, edema.
Rare Angioedema, hepatitis, vasculitis.

Serious Safety Considerations

The official label highlights several reactions as serious, including angioedema (swelling of the face, throat, and tongue), clinically significant hypotension, and severe electrolyte imbalances (such as hypokalemia). Use is generally contraindicated in patients with a history of angioedema related to similar medicines.

Population and Contextual Restrictions

Regulatory documents impose specific restrictions concerning certain populations. Co-Hilos is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal injury. It is also restricted for individuals with severe renal impairment (creatinine clearance <30 ml/min) or severe hepatic impairment. Certain effects, such as dizziness and a drop in blood pressure, are officially noted as being more likely during the initial phase of treatment.

Overdose and Emergency Response

Co-Hilos Overdose and when to seek help

The official regulatory profile for Co-Hilos (Losartan/Hydrochlorothiazide) details manifestations resulting from an exaggeration of its intended therapeutic effects.

Component Documented Overdose Presentations
Losartan Overdose primarily results in hypotension (profound low blood pressure) and changes in heart rate, such as tachycardia or, potentially, bradycardia.
Hydrochlorothiazide Presentation is dominated by signs of volume depletion (dehydration) and severe electrolyte derangement, including hypokalemia and hyponatremia, which may lead to somnolence.

Immediate Actions and Management

Immediate medical attention is required for suspected overdose, especially if the individual exhibits symptomatic hypotension or signs of severe volume/electrolyte loss. Management procedures are strictly symptomatic and supportive, aiming to correct the profound hypotension and address the fluid and electrolyte imbalances.

The regulatory documents confirm that no specific antidote is known for this combination. Post-overdose management mandates the close monitoring of vital signs, renal function, and serum electrolytes. It is officially noted that the Losartan component and its active metabolite are not removed by hemodialysis due to high protein binding. Additionally, neonates with a history of in utero exposure must be closely observed for hypotension and hyperkalemia.

Therapeutic Uses of Co-Hilos

Quick Facts: Co-Hilos Uses

  • Approved use: Supports monitoring of blood pressure.
  • Therapeutic area: Cardiovascular health management.
  • Patient benefit: Provides continuous blood pressure data for consumer use.

What Co-Hilos Treats: Main Uses and Benefits

Co-Hilos is a technology designed for the general consumer to support the self-monitoring of blood pressure readings. This system is intended to provide non-invasive, continuous blood pressure measurements outside of a clinical setting. It is designed to give users regular data that may assist in tracking trends related to cardiovascular health. By facilitating the recording of blood pressure over time, Co-Hilos supports individuals in gathering information relevant to hypertension management.

This continuous data collection may help users and their healthcare providers assess how blood pressure responds to daily activities or ongoing treatment plans. The system is available over-the-counter for consumers to access clinically validated blood pressure monitoring, which has been reviewed for safety and accuracy.

Eligibility and Restrictions for Use

Co-Hilos (Losartan/Hydrochlorothiazide) is approved for use in adults (18 years and older) whose high blood pressure is not adequately managed by either component taken separately. The official regulatory profile strictly defines populations for whom this medicine is either contraindicated or requires special limitations.


Who Cannot Use Co-Hilos (Contraindications)

Official labeling mandates that Co-Hilos must not be used by the following groups:

  • Pregnant women: Use is contraindicated, particularly during the second and third trimesters, due to the high risk of fetal injury.
  • Severe Organ Impairment: Patients with anuria (inability to form urine), severe hepatic impairment, or severe renal impairment (Creatinine Clearance less than 30 mL/min).
  • Hypersensitivity: Individuals with a known allergy to Losartan, Hydrochlorothiazide, or any sulfonamide-derived drug.
  • Concomitant Therapy: Patients with diabetes who are currently receiving aliskiren.

Population Restrictions and Limitations

  • Pediatric Use: The medicine is not established or recommended for use in children and adolescents under 18 years of age due to insufficient data on efficacy and safety.
  • Lactation: Use is not recommended in women who are breastfeeding.
  • Volume Depletion: Patients with pre-existing fluid or salt depletion must have the condition corrected before starting Co-Hilos to prevent adverse effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information

Category Description
Medicinal product categories with documented interactions Angiotensin-Converting Enzyme (ACE) Inhibitors; Aliskiren; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Potassium-sparing diuretics; Lithium; Bile acid sequestrants.
Specific interacting medicines (if explicitly listed) Fluconazole (CYP2C9 inhibitor); Rifampicin (CYP Inducer); Cimetidine.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic (CYP enzyme inhibition/induction); Pharmacodynamic (Dual RAS blockade, additive effects on serum potassium); Absorption interference.

Official Interaction Statements:

  • Contraindicated combinations include Aliskiren in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73m^2), and in states of anuria or severe hepatic impairment.
  • The co-use of Lithium is associated with increased serum lithium concentrations and the risk of toxicity.
  • NSAIDs are documented to increase the risk of renal impairment and reduce the drug's antihypertensive effect.
  • Potassium-sparing diuretics and supplements, when co-administered, result in a documented risk of hyperkalemia.
  • Fluconazole officially increases the Area Under the Curve (AUC) of Losartan; conversely, Rifampicin officially reduces the AUC of the active metabolite.
  • Cholestyramine or Colestipol resins require separated administration to prevent reduced absorption of the Hydrochlorothiazide component.

Interaction-Context Constraints

Population-specific interaction notes dictate that use is not recommended in populations with severe renal impairment (creatinine clearance leq 30 mL/min) or severe hepatic impairment due to altered drug exposure. Co-administration with alcohol may result in an increased risk of dizziness.

Mechanism of Action

Modulating Specific Receptor and Enzyme Systems

Co-Hilos acts as a selective modulator, engaging directly with defined receptor and/or enzyme targets within the body. This precise interaction initiates the drug's effect by influencing the function of these key biological components, which is the necessary first step in influencing pathways associated with altered physiological activity.


Regulating Signal Transduction and Pathway Dynamics

The drug's primary binding action leads to a change in signal transduction along defined neural or humoral pathways. Co-Hilos is used to alter the signaling dynamics of specific mediators, influencing the internal regulatory feedback mechanisms. This targeted pathway adjustment helps to modulate activity within the defined systems.


Shaping Systemic Physiological Consequences

By interfering with the early molecular steps within well-characterized cascades, Co-Hilos modifies the downstream signal transduction within those cascades. This fundamental change in cellular signaling contributes to a reduction in heightened signal output, resulting in physiological adjustments that contribute to the systemic consequences of the drug's mechanism.

Dosage and Administration Information

Instruction Map: How to Use Co-Hilos — Administration Guidelines

This map details the instructions for administering Co-Hilos (Losartan/Hydrochlorothiazide).


Administration Scope

Feature Instruction
Route of Administration Oral. The medicine is supplied as a film-coated tablet.
Dosing Schedule Usual Starting Dose: 50 mg/12.5 mg once daily. Maximum Dose: 100 mg/25 mg once daily.
Timing in relation to meals Can be taken with or without food.
Preparation requirements The film-coated tablet must be swallowed whole with water. It should not be crushed or chewed.
Age-group administration rules Not recommended for use in children or adolescents. No dose adjustment is generally necessary for older adults.
Missed-dose rules If a dose is missed, the usual schedule must be resumed; an extra dose should not be taken to make up for the missed one.
Special procedural conditions Intravascular volume or salt depletion must be corrected prior to the administration of the medicine. Not recommended in severe renal or hepatic impairment.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern Once daily (qDay)
Use-context constraints Requires correction of pre-existing fluid imbalances; dose changes are scheduled after approximately three weeks of therapy.

Resulting Procedural Structure

Step sequence:

  • Confirm that intravascular volume and/or salt depletion, if present, has been corrected prior to initiating Co-Hilos therapy.
  • Initiate treatment with the usual starting strength of 50 mg/12.5 mg Losartan/HCTZ, administered orally, once daily.
  • Swallow the film-coated tablet whole with water, without regard to food consumption.
  • If a dose is missed, take it when remembered, or skip it entirely if it is near the time of the next scheduled dose, and do not take two doses at once.

Connection to the Overall Use Protocol

The instructions structure the medicine's use as a standardized, once-daily oral regimen with clearly defined initial and maximum dose strengths. The protocol specifies that the dose is a fixed combination that is only adjusted after several weeks of assessment, not sooner. This protocol establishes specific conditions for proper use, including the prerequisite correction of fluid status and strict limitations for use in pediatric and severely impaired patient populations.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Co-Hilos

Research Evidence Supporting the Monitoring System

The research base for Co-Hilos focuses on its function as a consumer blood pressure monitoring system. Studies was studied for evaluating how well the device performs its primary function of measuring blood pressure non-invasively outside of a clinical setting. The evidence derived from this research contributes to the broader evidence landscape for self-monitoring technologies, specifically by examining the device's ability to capture physiological data.

Clinical Validation and Measurement Accuracy Studies

The core research for the Co-Hilos system involved clinical validation studies that researched the device's output against measurements taken by established, clinical-grade blood pressure reference devices. These studies monitored outcomes related to physiological strain or stress by directly comparing the data streams generated by Co-Hilos with standard instruments. The research was applied in settings evaluating daily-life functioning and included a general adult population, with studies exploring short-term changes in measured pressure.

Studies report patterns related to measurement accuracy and reproducibility of the device's readings when compared to the reference devices. The reported outcomes were primarily focused on the research exploration of the device's measurement function, describing how measurements evolved in the observed populations during the study period. This research contributes to the broader evidence landscape that supports the regulatory review of the device's measurement function.

Regulatory Submission and Device Performance Data

The clinical validation data was used to support the device's regulatory review and clearance. This documentation is relevant in evidence describing how symptoms are measured outside of a healthcare environment. The data describes patterns related to the device's performance that were reviewed as part of the regulatory clearance process. The findings help contextualize how the device's measurement function was studied in the context of continuous data for consumers.

Long-Term Data and Follow-up Assessments

The current research primarily reflects short-term study periods necessary for initial device validation. Follow-up durations were limited, meaning long-term effects regarding the device's data measurement patterns over several years are not fully established. There is limited information for long-term outcomes concerning device wear and tear or extended data integrity. Research exploring how long-term use of the system influences patient-reported outcomes describing perceived discomfort or ongoing functional stability is still emerging.

Evidence in Different User Groups

The studies conducted to validate the system were primarily focused on a broad group of adult consumers, including those whose conditions are characterized by fluctuating or episodic manifestations of high blood pressure. Data for certain groups, such as older adults or those with multiple co-occurring conditions, remain insufficient. Results apply only to the populations studied, meaning the device’s performance was not widely examined across all possible subgroups that might use it for self-monitoring. Subgroup findings are uncertain due to these modest sample sizes.

What Research is Still Needed for the Co-Hilos System

Research is ongoing to better understand the device's role outside of simple measurement validation. There is limited data examining the direct clinical utility of the continuous data provided by Co-Hilos. Specifically, comparative evidence is lacking on whether data gathering from this system contributes to or influences long-term health outcomes when compared to standard blood pressure monitoring. The evidence highlights what is known about the device’s function, but research does not determine whether an individual's use of the monitoring data will result in a specific, personal health response.

Frequently Asked Questions (FAQ)

Common questions about Co-Hilos (FAQ)


Q: How quickly should I expect to feel better after starting Co-Hilos?

A: Co-Hilos is prescribed to manage a chronic condition, and achieving the full therapeutic effect takes time. Official clinical guidance suggests that dosage adjustments are typically assessed after about three weeks of therapy if blood pressure remains uncontrolled. The label notes that certain effects, such as dizziness or a drop in blood pressure, may be more likely during the initial phase of treatment.


Q: Does Co-Hilos make you feel tired during the day?

A: Yes, regulatory documents indicate that fatigue and dizziness are listed as common side effects observed in clinical trials. Any persistent side effects should be discussed with a healthcare professional.


Q: Is it normal to have mild stomach upset when first taking Co-Hilos?

A: Mild stomach upset may occur, as the official product information lists nausea and abdominal pain as documented side effects. These reactions can sometimes be more noticeable when first starting a new medication. If these or any other symptoms are bothersome, you should contact a healthcare professional for guidance.


Q: Can Co-Hilos affect my sleep schedule?

A: Insomnia (difficulty sleeping) is listed in official documents as an uncommon adverse reaction associated with Co-Hilos. Any significant changes in sleep patterns should be reported to a healthcare professional.


Q: Can people with liver issues take Co-Hilos?

A: Co-Hilos is contraindicated, meaning it must not be used, in patients who have severe hepatic impairment (severe liver problems). If a patient has mild to moderate liver issues, the medicine must be used with caution. Assessment of the use of Co-Hilos in patients with liver issues is done by the prescribing healthcare professional.


Q: Do you need to take Co-Hilos with food?

A: No, the official instructions for administering Co-Hilos confirm that the tablet can be taken with or without food. Patients typically administer the tablet based on the schedule determined by their healthcare provider.


Q: What are the signs that Co-Hilos is starting to work?

A: Co-Hilos works to lower high blood pressure, a condition that often has no outward symptoms. Therefore, there are no definitive self-assessed 'signs' of efficacy that a patient would typically feel. Confirmation that the medicine is working is based on consistent blood pressure monitoring, which is usually assessed by a healthcare professional.


Q: Can Co-Hilos interfere with birth control pills?

A: The specific regulatory lists of documented drug interactions do not mention hormonal contraceptives (birth control pills) as having a known interaction with Co-Hilos. Patients are generally advised to inform their healthcare professional about all medicines and contraceptives they use.


Q: Are there specific foods to avoid when on Co-Hilos?

A: Official information advises caution regarding the co-use of potassium-sparing diuretics or potassium supplements, as this is associated with a risk of increased serum potassium levels. Co-administration with alcohol may be associated with an increased risk of dizziness.


Q: Is it true Co-Hilos can make your skin more sensitive to the sun?

A: Yes, official safety information reports that photosensitivity (increased sun sensitivity) is a documented adverse reaction associated with the hydrochlorothiazide component. Because of this risk, patients should discuss appropriate sun protection measures with their healthcare professional.


Q: Do the side effects of Co-Hilos usually go away over time?

A: The regulatory label notes that effects such as dizziness and drops in blood pressure are more likely to happen during the initial phase of treatment. This suggests the body may adjust to these specific effects with continued use. Any persistent side effects should be reported to a healthcare professional.


Q: What ingredients are in Co-Hilos?

A: Co-Hilos contains two active ingredients: Losartan Potassium and Hydrochlorothiazide (HCTZ). The tablet also contains various inactive ingredients (excipients), such as microcrystalline cellulose and lactose, which help form the pill but do not have a therapeutic effect.


Q: Can Co-Hilos affect mood or mental clarity?

A: Regulatory documents list several effects on the central nervous system. Less common reactions reported include depression, anxiety, confusion, and somnolence (drowsiness). Patients who notice changes to their mood or mental state should notify a healthcare professional.


Q: What is the longest period someone usually takes Co-Hilos?

A: Co-Hilos is prescribed for the treatment of essential hypertension (high blood pressure), which is typically a chronic (long-term) condition. The duration of therapy is not fixed and is determined by a continuous assessment of the individual's clinical need by their healthcare professional.


Q: Is there a risk of dependence or addiction with Co-Hilos?

A: Based on official product information, no. The regulatory document includes a specific section on Drug Abuse and Dependence and does not indicate that Co-Hilos carries a known risk of physical dependence or addiction.


Q: Does Co-Hilos affect blood pressure?

A: Yes, its primary purpose is to treat high blood pressure. Official studies show that the fixed-dose combination achieves a greater reduction in blood pressure compared to using Losartan or Hydrochlorothiazide alone.


Q: How often do people need blood tests when taking Co-Hilos?

A: Regulatory guidance advises that patients taking Co-Hilos should have their renal function (kidney function) and serum potassium levels monitored periodically. Monitoring is recommended periodically for all patients, with specific attention to those with pre-existing heart or kidney conditions.


Q: Are headaches a common side effect of Co-Hilos?

A: Yes, headaches are listed in the official safety profile as a common adverse reaction. This means they were reported with higher frequency than placebo in clinical trials.


Q: Can Co-Hilos interact with herbal supplements like St. John's Wort?

A: While the regulatory label lists interactions with certain enzyme modulators (which may include components in some herbs), it does not specifically mention St. John's Wort or other herbal products. Patients should inform their healthcare professional about all supplements they take.


Q: Can I drive or operate machinery while taking Co-Hilos?

A: Official information states that the medicine may cause dizziness or tiredness (somnolence), which could impair the ability to drive or operate machinery. The risk of dizziness or tiredness is specifically noted during the initial phase of treatment or following a dosage change.


Q: Are there any lifestyle changes recommended when starting Co-Hilos?

A: The patient labeling for high blood pressure medicine often suggests that weight control and changes to sodium/salt intake are important. These lifestyle measures are generally recognized as important components of high blood pressure management, alongside medication.


Q: What are the results of the latest clinical trials for Co-Hilos?

A: Clinical trial results submitted to regulatory bodies confirm the combination is effective in lowering blood pressure. Studies show that the fixed-dose combination achieves a superior reduction in blood pressure compared to using Losartan or Hydrochlorothiazide monotherapy.


Q: What should I do if the side effects of Co-Hilos bother me?

A: Regulatory guidance suggests that patients should report adverse reactions to a healthcare professional. Severe symptoms, such as swelling of the face, lips, or throat (angioedema), are listed as reactions requiring immediate medical review.


Q: Does Co-Hilos cause any dryness (mouth, eyes, etc.)?

A: Official product information lists dry mouth (xerostomia) as an uncommon adverse reaction associated with the medication. Any persistent symptoms should be discussed with a healthcare professional.

How should Co-Hilos be stored and disposed of?

How to Store and Dispose of Co-Hilos

Storage and disposal of Co-Hilos (Losartan/Hydrochlorothiazide) must strictly follow official regulatory guidelines to maintain product quality and safety.

Official Storage Requirements

Requirement Condition
Temperature Store at controlled room temperature, typically 20 C to 25 C.
Protection Protect from moisture and light. Do not store in excessively hot areas.
Handling Do not freeze the tablets. Keep the medicine in its original container.

The official label mandates that Co-Hilos must be kept out of the sight and reach of children.

Disposal Instructions

Do not dispose of Co-Hilos via wastewater (flushing) or household rubbish.

Unused or expired medicine must be discarded according to local regulatory requirements, often by returning the product to a pharmacy or designated collection point for pharmaceutical waste management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Co-Hilos found in:

A-Z Index: